The review topic and background is limited in scope and does not address the current priority questions with regard to integrase inhibitors. In addition there have been two recently published reviews covering this topic, both of which demonstrated that dolutegravir is currently the integrase inhibitor of choice (https://www.ncbi.nlm.nih.gov/pubmed/?term=27658869; http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162775). This protocol is therefore withdrawn from The Cochrane Library.